Archive | Uncategorized

BBJ: Md. Tech Council CEO wants state biotech industry to aim higher than “top 3”

MTCjpg

“Why would you shoot for No. 3?” Maryland Tech Council CEO Marty Rosendale wants to unite companies and legislators around making Maryland into the No. 1 destination for biotech firms in the U.S. Click here to read more via the Baltimore Business Journal (Subscription Required)

Comments Off on BBJ: Md. Tech Council CEO wants state biotech industry to aim higher than “top 3” Continue Reading →

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing

Sagimet Biosciences Logo

Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways SAN MATEO, Calif., Aug. 5, 2019 /PRNewswire/ — 3-V Biosciences, a clinical-stage biotechnology company, announced today that it has changed its name to Sagimet Biosciences and closed a second tranche of its Series E financing, which now totals $25 million. Sagimet’s lead product candidate, the […]

Comments Off on 3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing Continue Reading →

MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk

BioTalk Logo

MaxCyte Founder, President and CEO Doug Doerfler joins BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July […]

Comments Off on MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk Continue Reading →

MaxCyte Adds VP, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

2X2 Final MaxCyte Portrait July 1 2019 DSC_1669 Coyle Studios

Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies  Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and […]

Comments Off on MaxCyte Adds VP, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform Continue Reading →

BioBuzz: Five Companies That Are Powering The Cell and Gene Therapy Revolution (MaxCyte Included)

MAXCYTE-New-Logo-2016-LARGE

Several Maryland companies are making a global impact in the field of cell and gene therapy July 16, 2019 The promise of cell and gene therapies to cure unmet medical needs is finally starting to come through as life-saving new medicines are now hitting the market every year. The global market for gene therapies was […]

Comments Off on BioBuzz: Five Companies That Are Powering The Cell and Gene Therapy Revolution (MaxCyte Included) Continue Reading →

Genomics leader Illumina is opening a new center at University of Maryland BioPark

UMBioPark-Twitter-Profile-Image

It’s the first East Coast location for the San Diego-based company. Here’s how leaders say it can raise the profile for Baltimore’s biotech community. A leading genomics company with international reach is opening its first commercial location on the East Coast at Baltimore’s University Maryland BioPark. San Diego-based Illumina, which was founded in 1998 and has 7,000 […]

Comments Off on Genomics leader Illumina is opening a new center at University of Maryland BioPark Continue Reading →

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

MAXCYTE-New-Logo-2016-LARGE

MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new ExPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, […]

Comments Off on MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies Continue Reading →

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing

Paragon

Appointments and Promotions Continue to Position Paragon as Industry-Leading Gene Therapy and Vaccine CDMO Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several key promotions and new hires. “We are thrilled to welcome Tom […]

Comments Off on Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing Continue Reading →

Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic

bluestar_jpg

Welldoc®, a leading digital health company, announced today that it has secured a technology patent (based on U.S. Patent Application No. 15/923,010) from the United States Patent and Trademark Office for the Software Engine Technology that powers its BlueStar® digital therapeutic. “The awarding of this tenth technology patent to Welldoc is a validation of our […]

Comments Off on Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic Continue Reading →